Patents by Inventor Su Youn Nam
Su Youn Nam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058420Abstract: A pharmaceutical composition for treating cancer, containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent. A fusion protein containing a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein containing an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: ApplicationFiled: November 1, 2023Publication date: February 22, 2024Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Patent number: 11857601Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: GrantFiled: March 18, 2021Date of Patent: January 2, 2024Assignee: GI INNOVATION, INC.Inventors: Myung Ho Jang, Su Youn Nam, Young Jun Koh
-
Publication number: 20230279124Abstract: The present invention relates to a fusion protein dimer comprising an IgE Fc receptor alpha subunit extracellular domain (Fc?RI?-ECD) and a fragment of anti-IL-4R antibody; and a composition for treating allergic diseases, comprising the same. The fusion protein dimer according to the present invention exhibits an excellent IgE-binding ability and an excellent serum IgE level-reducing effect. In addition, the present invention elicits a hyperimmune response of IgE, and thus has an excellent effect of inhibiting the activity of cytokines inducing allergic diseases, such as IL-4 and IL-13, and thus may be applied as a medicine for the use of treating or preventing IgE-mediated allergic diseases.Type: ApplicationFiled: July 14, 2021Publication date: September 7, 2023Inventors: Myung Ho JANG, Su Youn NAM, Young-Gyu CHO, Young Min OH, Kyungwha LEE, Nahyun OH
-
Publication number: 20230257459Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor is disclosed. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, the fusion protein dimer and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: ApplicationFiled: March 1, 2023Publication date: August 17, 2023Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Su Youn NAM, Young Jun KOH, Young-Gyu CHO
-
Publication number: 20230233680Abstract: A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.Type: ApplicationFiled: June 1, 2021Publication date: July 27, 2023Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Publication number: 20230190876Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.Type: ApplicationFiled: March 18, 2021Publication date: June 22, 2023Applicant: GI INNOVATION, INC.Inventors: Myung Ho JANG, Su Youn NAM, Young Jun KOH
-
Patent number: 11639383Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: GrantFiled: November 27, 2020Date of Patent: May 2, 2023Assignee: GI INNOVATION, INC.Inventors: Myoung Ho Jang, Su Youn Nam, Young Jun Koh, Young-Gyu Cho
-
Publication number: 20220403019Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.Type: ApplicationFiled: November 27, 2020Publication date: December 22, 2022Applicant: GI INNOVATION, INC.Inventors: Myoung Ho JANG, Su Youn NAM, Young Jun KOH, Young-Gyu CHO
-
Publication number: 20220002367Abstract: A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.Type: ApplicationFiled: September 17, 2021Publication date: January 6, 2022Applicant: YUHAN CORPORATIONInventors: Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Byung Hyun CHOI, Jun Kyung LEE, Jong Gyun KIM, Su Youn NAM
-
Publication number: 20220002368Abstract: A dual function protein is disclosed. The dual function protein may be prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. The dual function protein has improved pharmacological efficacy, in vivo duration and protein stability. The dual function protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.Type: ApplicationFiled: September 17, 2021Publication date: January 6, 2022Applicant: YUHAN CORPORATIONInventors: Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Seul Gi KIM, Sangmyoun LIM, Jong Gyun KIM, Su Youn NAM
-
Patent number: 11142557Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.Type: GrantFiled: October 28, 2016Date of Patent: October 12, 2021Assignee: YUHAN CORPORATIONInventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Byung Hyun Choi, Jun Kyung Lee, Jong Gyun Kim, Su Youn Nam
-
Patent number: 11136364Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.Type: GrantFiled: October 28, 2016Date of Patent: October 5, 2021Assignee: YUHAN CORPORATIONInventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Seul Gi Kim, Sangmyoun Lim, Jong Gyun Kim, Su Youn Nam
-
Patent number: 11046742Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: GrantFiled: April 19, 2017Date of Patent: June 29, 2021Assignee: YUHAN CORPORATIONInventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Patent number: 10941136Abstract: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.Type: GrantFiled: April 26, 2017Date of Patent: March 9, 2021Assignee: YUHAN CORPORATIONInventors: Young-Hwan Kim, Tae-Dong Han, Dong-Hoon Kim, Eun-Hye Jung, Su-Bin Choi, Eui-Chul Lee, Won-Ee Chong, Jin-Hwi Park, Jun-Chul Park, Ho-Woong Kang, Ji-Yeong Gal, Chan-Sun Park, Jong-Gyun Kim, Su-Youn Nam
-
Publication number: 20200325120Abstract: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.Type: ApplicationFiled: April 26, 2017Publication date: October 15, 2020Applicant: YUHAN CORPORATIONInventors: Young-Hwan KIM, Tae-Dong HAN, Dong-Hoon KIM, Eun-Hye JUNG, Su-Bin CHOI, Eui-Chul LEE, Won-Ee CHONG, Jin-Hwi PARK, Jun-Chul PARK, Ho-Woong KANG, Ji-Yeong GAL, Chan-Sun PARK, Jong-Gyun KIM, Su-Youn NAM
-
Publication number: 20200024318Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.Type: ApplicationFiled: October 28, 2016Publication date: January 23, 2020Applicant: YUHAN CORPORATIONInventors: Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Seul Gi KIM, Sangmyoun LIM, Jong Gyun KIM, Su Youn NAM
-
Patent number: 10383859Abstract: The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.Type: GrantFiled: July 6, 2017Date of Patent: August 20, 2019Assignee: Yuhan CorporationInventors: Se-Woong Oh, Youn Hur, Jin-Hwi Park, Jae-Eun Joo, Ho-Woong Kang, Hyok-Jun Cho, Eui-Chul Lee, Chan-Sun Park, Dong-Hyun Kim, Jong-Gyun Kim, Su-Youn Nam
-
Publication number: 20190153055Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: ApplicationFiled: April 19, 2017Publication date: May 23, 2019Inventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Publication number: 20190142809Abstract: The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.Type: ApplicationFiled: July 6, 2017Publication date: May 16, 2019Applicant: Yuhan CorporationInventors: Se-Woong Oh, Youn Hur, Jin-Hwi Park, Jae-Eun Joo, Ho-Woong Kang, Hyok-Jun Cho, Eui-Chul Lee, Chan-Sun Park, Dong-Hyun Kim, Jong-Gyun Kim, Su-Youn Nam
-
Publication number: 20180305428Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.Type: ApplicationFiled: October 28, 2016Publication date: October 25, 2018Applicant: YUHAN CORPORATIONInventors: Jun Hwan KIM, Seyoung LIM, Minji SEO, Hyun Ho CHOI, Dohoon KIM, Mi Kyeong JU, Ju-Young PARK, Byung Hyun CHOI, Jun Kyung LEE, Jong Gyun KIM, Su Youn NAM